Compare Novo Nordisk A/S (NVO) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs 22nd Century Group Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: Novo Nordisk A/S is far larger — about 148006.7× 22nd Century Group Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| NVO | XXII | |
|---|---|---|
Market Cap | $220.53B | $1.49M |
Sector | Health | Technology |
52-Week High | $71.70 | $1.07K |
52-Week Low | $35.29 | $3.90 |
Enterprise Value | $239.49B | -$6.74M |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
